Valuation & Deal Architecture in Biopharma Technology Licensing
Location:Guildford
Date:19th Nov 2026
Price:£FREE(Non-Members: £50.00)
Location:GuildfordDate:19th Nov 2026Price:£FREE(Non-Members: £50.00)Valuation & Deal Architecture in Biopharma Technology Licensing
A focused session for UK pharma and biotech licensing professionals exploring how to value, structure, and contract complex technology-based deals in today’s market
Technology licensing is a key enabler in modern biopharma, supporting the translation of promising molecules into viable therapies. Delivery platforms, manufacturing innovations, and specialised administration technologies can significantly impact clinical success, scalability, and cost.
As these technologies become central to value creation, their licensing requires robust valuation approaches and carefully designed deal structures. This session focuses on how to effectively price, structure, and contract such partnerships
| 1pm | Networking lunch |
| 2pm | Welcome & Introduction SIMON CAWTHORNE, Board Member, PLG |
| 2.10pm | Value, Risk and Reward: Structuring Technology Licensing Deals that Work More than just the royalty rate determines licensing success ANDREW TINGEY, Founder, Broad Arrow Consulting |
| 2.40pm | Technology Licensing in Practice: Key Provisions and Negotiation Dynamics A practical guide to the key clauses and negotiation points shaping technology licensing agreements from both licensor and licensee perspectives CHARLOTTE TILLETT, Partner and TOM COLLINS, Managing Associate, Stevens & Bolton LLP |
| 3.10pm | Ensuring Value Translates: Net Revenue Considerations and Audit Provisions How net revenue definitions affect royalty outcomes, and when, where and how audit rights can be used to protect value MARK REVELEY, Partner, HW Fisher Forensic |
| 3.40pm | Q&A and closing remarks |
| 4pm | Networking reception |
| 5pm | Finish |
Location:GuildfordDate:19th Nov 2026Price:£FREE(Non-Members: £50.00)